13F Holdings
中文EN

VVOS Vivos Therapeutics, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1716166 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY18.6%
TTM net income YoY-28.6%
TTM EPS YoY23.7%
Revenue 3-yr CAGR12.3%
Net income 3-yr CAGR—

Margins

Gross margin60.0%
Operating margin-105.8%
Net margin-107.2%
FCF margin-88.5%
EBITDA margin-96.2%

Returns

ROE-899.5%
ROA-90.7%
ROIC (approx.)-283.8%
Asset turnover0.85x

Leverage & solvency

Liabilities / assets90.5%
Debt / equity0.77x
Current ratio0.22x
Interest coverage-6.03x

Cash quality & payout

Operating cash flow / net income0.73x
Accruals ratio-24.1%
Payout ratio—
Capex / revenue9.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$6.41M$5.15M$5.14M$3.82M$6.78M$3.82M$3.02M$3.70M
Cost of revenue$3.10M$2.20M$2.08M$836,000$2.85M$1.71M$1.51M$1.60M
Gross profit$3.31M$2.95M$3.06M$2.99M$3.94M$2.11M$1.51M$2.10M
SG&A expense$6.45M$7.11M$8.97M$8.55M$7.88M$6.41M$4.89M$4.35M
Operating income-$3.90M-$4.83M-$6.62M-$6.38M-$4.73M-$4.87M-$3.92M-$2.81M
Interest expense$600,000$1.10M$1.10M$800,000$500,000———
Pretax income-$1.97M-$5.52M-$7.75M-$6.95M-$5.40M-$5.01M-$3.86M-$2.83M
Net income-$1.95M-$5.48M-$7.68M-$6.89M-$5.40M-$5.01M-$3.86M-$2.83M
EBITDA-$3.35M-$4.32M-$6.16M-$5.94M-$4.35M-$4.56M-$3.74M-$2.66M
EPS (basic)-0.07-0.31-0.52—-0.49-0.55-0.45—
EPS (diluted)-0.07-0.31-0.52—-0.49-0.55-0.45—
Weighted avg. shares (diluted)26.53M17.68M14.63M—10.96M9.09M8.60M—
Balance sheet
Cash & equivalents$247,000$1.77M$2.11M$2.03M$3.09M$4.40M$2.34M$6.26M
Receivables$2.37M$1.44M$1.77M$1.58M$2.13M$1.63M$718,000$430,000
Current assets$3.51M$4.21M$4.82M$4.38M$5.79M$6.73M$3.61M$7.47M
PP&E, net$3.35M$3.64M$3.53M$3.76M$5.64M$5.13M$3.31M$3.31M
Goodwill$8.57M$8.57M$8.57M$8.57M$8.45M$8.45M$2.84M$2.84M
Intangibles$3.44M$3.64M$3.84M$4.04M$2.17M$2.23M$358,000$409,000
Total assets$22.86M$24.14M$25.04M$25.15M$25.64M$26.03M$11.28M$15.28M
Current liabilities$16.16M$20.39M$17.94M$18.08M$7.44M$6.43M$4.70M$4.98M
Short-term debt$1.50M$7.77M$7.30M$8.35M$339,000$157,000——
Long-term debt$313,000$366,000$418,000$469,000$8.38M$7.76M—$1.20M
Total debt$1.81M$8.14M$7.72M$8.82M$8.72M$7.92M—$1.20M
Total liabilities$20.69M$28.13M$26.31M$26.70M$23.11M$21.45M$6.88M$7.33M
Shareholders' equity$2.36M-$3.81M-$1.14M-$1.49M$2.53M$4.58M$4.41M$7.95M
Net debt$1.57M$6.36M$5.61M$6.79M$5.63M$3.52M—-$5.06M
Shares outstanding33.82M14.53M13.49M9.29M8.27M7.32M5.89M5.89M
Cash flow statement
Operating cash flow-$3.18M-$3.15M-$6.01M-$3.81M-$4.16M-$3.49M-$3.80M-$2.94M
Capital expenditure$61,000$416,000$18,000$1.53M-$83,000$771,000$122,000$165,000
Free cash flow-$3.24M-$3.56M-$6.03M-$5.34M-$4.08M-$4.26M-$3.92M-$3.10M
Investing cash flow-$61,000-$416,000-$18,000-$1.58M$83,000-$5.91M-$122,000-$165,000
Financing cash flow$1.71M$3.23M$6.11M$4.33M$2.76M——$3.05M
Depreciation & amortization$550,000$510,000$454,000$442,000$384,000$306,000$177,000$144,000
Stock-based compensation$100,000$100,000$151,000$47,000$100,000$300,000$317,000$57,000

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.